Abstract
In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CMLpatients, up front in patients presenting with advanced disease, or as planned second-line therapy after imatinib failure.
Original language | English (US) |
---|---|
Pages (from-to) | 1860-1861 |
Number of pages | 2 |
Journal | Blood |
Volume | 115 |
Issue number | 10 |
DOIs |
|
State | Published - Mar 11 2010 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology